^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CMAB 819 (nivolumab biosimilar)

    i
    Other names: CMAB 819, CMAB-819, CMAB819
    Associations

    News

    Trials
    Company:
    Mabpharm Limited
    Drug class:
    PD1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    7ms
    Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in R/M HNSCC (clinicaltrials.gov)
    P1, N=21, Terminated, Taizhou Mabtech Pharmaceutical Co.,Ltd | Trial completion date: Sep 2024 --> Oct 2023 | Active, not recruiting --> Terminated | Trial primary completion date: May 2024 --> Oct 2023; Difficult to recruit subjects
    Trial completion date • Trial termination • Trial primary completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • CMAB 819 (nivolumab biosimilar)
    over1year
    Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in R/M HNSCC (clinicaltrials.gov)
    P1, N=21, Active, not recruiting, Taizhou Mabtech Pharmaceutical Co.,Ltd | Recruiting --> Active, not recruiting | N=164 --> 21 | Trial completion date: Sep 2023 --> Sep 2024 | Trial primary completion date: May 2022 --> May 2024
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • CMAB 819 (nivolumab biosimilar)
    almost2years
    Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in R/M HNSCC (clinicaltrials.gov)
    P1, N=164, Recruiting, Taizhou Mabtech Pharmaceutical Co.,Ltd | Trial primary completion date: Sep 2022 --> May 2022
    Trial primary completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • CMAB 819 (nivolumab biosimilar)
    almost4years
    Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in R/M HNSCC (clinicaltrials.gov)
    P1, N=164, Recruiting, Taizhou Mabtech Pharmaceutical Co.,Ltd
    Clinical • New P1 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • CMAB 819 (nivolumab biosimilar)